PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer

BACKGROUND: Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and to establish factors predictive of this resistance. RESUL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chan, Lee, Choong-Kun, Chon, Hong Jae, Kim, Joo Hoon, Park, Hyung Soon, Heo, Su Jin, Kim, Hyun Jeong, Kim, Tae Soo, Kwon, Woo Sun, Chung, Hyun Cheol, Rha, Sun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768341/
https://www.ncbi.nlm.nih.gov/pubmed/29371924
http://dx.doi.org/10.18632/oncotarget.23054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768341/
https://www.ncbi.nlm.nih.gov/pubmed/29371924
http://dx.doi.org/10.18632/oncotarget.23054

Ejemplares similares